News | November 27, 2021
Fifty-five manufacturers selected for Pharma PLI sector
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
The division is expected to grow to over a 100-member strong team by 2022
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
The trial will be conducted across eight sites in Maharashtra
PPH is associated with almost 20 per cent of maternal mortality in India
Subscribe To Our Newsletter & Stay Updated
